ZA988124B - Mage-3 peptides presented by HLA class II molecules - Google Patents

Mage-3 peptides presented by HLA class II molecules

Info

Publication number
ZA988124B
ZA988124B ZA988124A ZA988124A ZA988124B ZA 988124 B ZA988124 B ZA 988124B ZA 988124 A ZA988124 A ZA 988124A ZA 988124 A ZA988124 A ZA 988124A ZA 988124 B ZA988124 B ZA 988124B
Authority
ZA
South Africa
Prior art keywords
mage
hla class
molecules
peptides
peptides presented
Prior art date
Application number
ZA988124A
Other languages
English (en)
Inventor
Pascal Chaux
Thierry Boon-Falleur
Rosalie Luiten
Carlo Heirman
Vincent Stroobant
Pierre Van Der Bruggen
Kris Thielemans
Jurgen Corthals
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of ZA988124B publication Critical patent/ZA988124B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA988124A 1997-09-12 1998-09-04 Mage-3 peptides presented by HLA class II molecules ZA988124B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/928,615 US5965535A (en) 1997-09-12 1997-09-12 Mage-3 peptides presented by HLA class II molecules

Publications (1)

Publication Number Publication Date
ZA988124B true ZA988124B (en) 1999-03-05

Family

ID=25456537

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA988124A ZA988124B (en) 1997-09-12 1998-09-04 Mage-3 peptides presented by HLA class II molecules

Country Status (9)

Country Link
US (2) US5965535A (fr)
EP (1) EP1012283B1 (fr)
JP (1) JP4106179B2 (fr)
AT (1) ATE432983T1 (fr)
AU (1) AU757368B2 (fr)
CA (1) CA2303063C (fr)
DE (1) DE69840868D1 (fr)
WO (1) WO1999014326A1 (fr)
ZA (1) ZA988124B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE272113T1 (de) * 1994-02-16 2004-08-15 Crucell Holland Bv Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
PT1053325E (pt) 1998-02-05 2006-05-31 Glaxosmithkline Biolog Sa Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
WO2000020445A2 (fr) * 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Antigenes tumoraux et clones de lymphocyte t cytotoxique (ctl) isoles grace a un nouveau procede
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
IT1312568B1 (it) * 1999-05-21 2002-04-22 Genera Spa Peptidi immunogenici e loro uso.
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US7429639B2 (en) * 1999-09-29 2008-09-30 Ludwig Institute For Cancer Research SSX-2 peptides presented by HLA class II molecules
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
HK1046925A1 (zh) * 1999-10-19 2003-01-30 Ludwig Institute For Cancer Research Mage-a12抗原肽及其用途
US6605711B1 (en) * 1999-11-15 2003-08-12 Ludwig Institute For Cancer Research NY-ESO-1 peptide derivatives, and uses thereof
CA2393339A1 (fr) * 1999-12-10 2001-06-14 Epimmune Inc. Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US7803382B2 (en) 2001-05-04 2010-09-28 Ludwig Institute For Cancer Research Ltd. Method for inducing immune response to NY-CO-58
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
AU2002322009A1 (en) * 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7575886B2 (en) 2002-03-11 2009-08-18 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
EP1864691B1 (fr) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Acide nucléique ACE modifié et vecteurs d'expression
WO2004037284A1 (fr) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Vaccins anticancereux et cytokines a haute dose utilisees comme adjuvants
JP2006505280A (ja) * 2002-11-07 2006-02-16 チャン・ルン−ジ 改変樹状細胞
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US7858743B2 (en) * 2004-09-09 2010-12-28 Ludwig Institute For Cancer Research SSX-4 peptides presented by HLA class II molecules
US20090169573A1 (en) * 2004-10-20 2009-07-02 Erwin Schultz T-Cell Stimulatory Peptides From The Melanoma-Associated Chondroitin Sulfate Proteoglycan And Their Use
WO2008053573A1 (fr) * 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
CA2836117C (fr) 2009-12-10 2017-08-15 Ottawa Hospital Research Institute Rhabdovirus oncolitique
US8435795B2 (en) 2010-01-19 2013-05-07 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CA2901501C (fr) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Composition de vaccin
WO2014207708A2 (fr) 2013-06-28 2014-12-31 Auckland Uniservices Limited Conjugués acide aminé et peptide et procédé de conjugaison
JP6313478B2 (ja) * 2014-05-30 2018-04-18 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｍａｇｅ−ａ３ペプチド標的アプタマー及びその使用
BR112017013574A2 (pt) 2014-12-23 2018-03-06 Verdon Daniel conjugados de aminoácido e peptídeo e usos dos mesmos
EP3419962A4 (fr) 2016-02-26 2020-03-11 Auckland Uniservices Limited Conjugués d'acides aminés et de peptides et procédé de conjugaison
US10441509B2 (en) * 2018-03-16 2019-10-15 Berkshire Biomedical, LLC Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019409D0 (en) * 1990-09-05 1990-10-17 Pfizer Ltd Therapeutic agents
US5139325A (en) * 1991-01-25 1992-08-18 Oksman Henry C Wide depth of focus power add to intraocular and contact lenses
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5348578A (en) * 1991-10-23 1994-09-20 Ppg Industries (France) S.A. Products obtained from the reaction of amine-diol and a polyfunctional substance and application of such products to electroapplicable cationic paint compositions
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
ES2225824T3 (es) * 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5414610A (en) * 1993-06-21 1995-05-09 Ast Research, Inc. Universal power converter with single, shared power transformation circuit
JP3211833B2 (ja) * 1993-07-21 2001-09-25 富士通株式会社 Ａｔｍ交換機
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5851523A (en) 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
WO1996015346A1 (fr) * 1994-11-11 1996-05-23 Kabushiki Kaisha Tokai-Rika-Denki-Seisakusho Dispositif d'acceptation de demarrage d'un vehicule et procede d'enregistrement d'un code d'identification
DE4441903C1 (de) * 1994-11-24 1996-03-21 Siemens Ag Drucksensor
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
AU7440196A (en) * 1995-10-12 1997-04-30 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
EP2724617A1 (fr) 2012-10-25 2014-04-30 Commissariat A L'energie Atomique Et Aux Energies Alternatives Composés pour soulager les symptômes de manque de phosphate dans des plantes
US9603182B2 (en) 2013-03-14 2017-03-21 Qualcomm Incorporated Establishing reliable always-on packet data network connections

Also Published As

Publication number Publication date
JP2001516579A (ja) 2001-10-02
EP1012283A1 (fr) 2000-06-28
DE69840868D1 (de) 2009-07-16
AU757368B2 (en) 2003-02-20
CA2303063A1 (fr) 1999-03-25
ATE432983T1 (de) 2009-06-15
JP4106179B2 (ja) 2008-06-25
US5965535A (en) 1999-10-12
AU9306198A (en) 1999-04-05
WO1999014326A1 (fr) 1999-03-25
EP1012283B1 (fr) 2009-06-03
CA2303063C (fr) 2009-11-24
US6369211B1 (en) 2002-04-09

Similar Documents

Publication Publication Date Title
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
WO2002095051A3 (fr) Peptides mage-a3 presentes par des molecules hla de classe ii
ATE427354T1 (de) Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden
EP1295944A3 (fr) Protéine stimulant la dissociation du GDP, protéine d'assemblage de nucléosome spécifique au cerveau, enzyme de conjugaison d'ubiquitine spécifique aux muscles du squelette, protéine de prolifération de cellule, phosphatidylinositolkinase, protéines apparentés à nel
WO1999053061A3 (fr) Acides nucleiques associes a des tumeurs et leur emploi
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
MX9705039A (es) Genes y proteinas de muerte celular programada.
EP1005540A4 (fr) Proteines ikk-beta, acides nucleiques et procedes
NZ502392A (en) Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals
EP0788307A4 (fr) Modulation par les oligonucleotides de la proteine associee a la resistance multiples aux anticancereux
ATE295889T1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
DE69924826T8 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
ATE394484T1 (de) Smad 6 und dessen anwendungen
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
WO1998059040A3 (fr) Sous-unite de telomerase catalytique humaine et son utilisation therapeutique et diagnostique
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
ATE496129T1 (de) Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
PT970206E (pt) Ácidos nucleicos lage-1 associados a tumores
WO2001072826A3 (fr) Gene 1 associe a l'osteomalacie oncogene
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
WO2004078918A3 (fr) Materiel et methodes de traitement et de diagnostic utilisant le ciblage de cellules exprimant les polypeptides dcal-hy
WO2004019283A3 (fr) Techniques de regulation de la transcription par ciblage d'adn quadruplex